Article
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jul 2008
Krivak Thomas C, Darcy Kathleen M, Tian Chunqiao, Armstrong Deborah, Baysal Bora E, Gallion Holly, Ambrosone Christine B, DeLoia Julie A
Abstract excerpt
PURPOSE: We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P). PATIENTS AND METHODS: Single...
Topics
Join the communities discussing this publication.